Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yanping Hu

Showing results (171-180 of 200) with videos related to

Pageof 20
Sort By:
The Lancet. Oncology|June 15, 2026
Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trialZiming Li, Jie Hu, Jianhua Chen, et al.
Nature Genetics|March 18, 2025
Genomic analysis of 1,325 Camellia accessions sheds light on agronomic and metabolic traits for tea plant improvementWeilong Kong, Xiangrui Kong, Zhongqiang Xia, et al.
The Lancet. Respiratory Medicine|July 19, 2018
Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trialZhijie Wang, Ying Cheng, Tongtong An, et al.
Lung Cancer (Amsterdam, Netherlands)|January 15, 2024
Myeloprotection with trilaciclib in Chinese patients with extensive-stage small cell lung cancer receiving chemotherapy: Results from a randomized, double-blind, placebo-controlled phase III study (TRACES)Ying Cheng, Lin Wu, Dingzhi Huang, et al.
The Lancet. Respiratory Medicine|May 8, 2023
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trialShun Lu, Lin Wu, Hong Jian, et al.
Cancer Cell|January 5, 2024
A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004)Caicun Zhou, Yanping Hu, Ekaterine Arkania, et al.
The Lancet. Oncology|July 31, 2022
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trialShun Lu, Lin Wu, Hong Jian, et al.
The Lancet. Respiratory Medicine|December 7, 2025
First-line serplulimab plus chemotherapy with or without HLX04 versus chemotherapy in locally advanced or metastatic non-squamous non-small-cell lung cancer (ASTRUM-002): a randomised, double-blind, multicentre phase 3 trialLin Wang, Xuezhi Hao, Yanrong Hao, et al.
Signal Transduction and Targeted Therapy|January 28, 2022
Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trialYuankai Shi, Jian Fang, Xuezhi Hao, et al.
International Journal of Oral Science|April 14, 2026
Expert consensus on the management of third molar healthRui Sun, Yifan Xu, Yang Wu, et al.
Pageof 20

Showing results (171-180 of 200) with videos related to

Sort By:
Pageof 20
The Lancet. Oncology|June 15, 2026
Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trialZiming Li, Jie Hu, Jianhua Chen, et al.
Nature Genetics|March 18, 2025
Genomic analysis of 1,325 Camellia accessions sheds light on agronomic and metabolic traits for tea plant improvementWeilong Kong, Xiangrui Kong, Zhongqiang Xia, et al.
The Lancet. Respiratory Medicine|July 19, 2018
Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trialZhijie Wang, Ying Cheng, Tongtong An, et al.
Lung Cancer (Amsterdam, Netherlands)|January 15, 2024
Myeloprotection with trilaciclib in Chinese patients with extensive-stage small cell lung cancer receiving chemotherapy: Results from a randomized, double-blind, placebo-controlled phase III study (TRACES)Ying Cheng, Lin Wu, Dingzhi Huang, et al.
The Lancet. Respiratory Medicine|May 8, 2023
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trialShun Lu, Lin Wu, Hong Jian, et al.
Cancer Cell|January 5, 2024
A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004)Caicun Zhou, Yanping Hu, Ekaterine Arkania, et al.
The Lancet. Oncology|July 31, 2022
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trialShun Lu, Lin Wu, Hong Jian, et al.
The Lancet. Respiratory Medicine|December 7, 2025
First-line serplulimab plus chemotherapy with or without HLX04 versus chemotherapy in locally advanced or metastatic non-squamous non-small-cell lung cancer (ASTRUM-002): a randomised, double-blind, multicentre phase 3 trialLin Wang, Xuezhi Hao, Yanrong Hao, et al.
Signal Transduction and Targeted Therapy|January 28, 2022
Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trialYuankai Shi, Jian Fang, Xuezhi Hao, et al.
International Journal of Oral Science|April 14, 2026
Expert consensus on the management of third molar healthRui Sun, Yifan Xu, Yang Wu, et al.
Pageof 20